Valneva Expands Chikungunya Vaccine Access with UK Adolescent Label Application

Valneva is making strides in the fight against chikungunya with its latest move to expand the use of IXCHIQ® to adolescents in the UK. The specialty vaccine company has submitted a label extension application to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), aiming to make its single-dose chikungunya vaccine available for individuals aged 12 to 17. This follows a recent positive recommendation from the EMA, reinforcing confidence in IXCHIQ®'s efficacy and safety for younger populations. Already approved for adults in the U.S., Europe, Canada, and the UK, this vaccine represents a critical tool in preventing the spread of chikungunya, which continues to cause outbreaks in regions like India, Brazil, and La Réunion.

Valneva’s commitment to broadening vaccine access is evident through its global partnerships. The company recently expanded its collaboration with CEPI, securing a $41.3 million grant to enhance vaccine availability in low- and middle-income countries (LMICs) and further research its potential use in children and pregnant women. In addition, Valneva’s exclusive licensing agreement with Serum Institute of India and its long-standing partnership with Instituto Butantan in Brazil are key steps toward making IXCHIQ® accessible and affordable in regions most affected by chikungunya. With strong Phase 3 trial results showing a 99.1% immune response rate in adolescents, Valneva is poised to expand protection against this debilitating virus worldwide.